Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022




(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)






50 Hampshire Street

Suite 401


Cambridge, Massachusetts



(Address of Principal Executive Offices)


(Zip Code)


Registrant’s Telephone Number, Including Area Code: (857) 320-6400



(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class




Name of each exchange on which registered

Common Stock, $0.0001 par value per share




The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 7.01 Regulation FD Disclosure.

Oncorus, Inc. (the Company) is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a presentation, dated January 2022, which the Company intends to use in meetings with or presentations to investors.


The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation by reference language in such a filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number








Investor Presentation, dated January 2022






Cover Page Interactive Data File (embedded within the inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.










January 10, 2022


/s/ John McCabe




John McCabe
Chief Financial Officer


Slide 1

Corporate Presentation January 2022 Viral Immunotherapies for Cancer NASDAQ: ONCR

Slide 2

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the current beliefs, expectations and assumptions of Oncorus, Inc. (the “Company”) regarding the future of its business, its future plans and strategies, clinical results, future financial condition and other future conditions, including, without limitation, implied and express statements regarding: the Company’s ability to advance its clinical and preclinical pipelines, including the clinical development of ONCR-177 and the timing of anticipated further monotherapy data read-outs for its ongoing Phase 1 clinical trial and initial read-outs of combination therapy data; ONCR-177’s therapeutic potential and clinical benefits and the utility and potential of the Company’s HSV platform generally; expectations regarding the registrational path for ONCR-177 and the design of its potential registrational trial; the implications of biomarker data with respect to ONCR-177 as it relates to anticipated tumor response; ONCR-177’s safety profile allowing for optionality with respect to potential combination partners and the ability to move into earlier disease settings; expectations regarding upcoming milestones for its preclinical product candidates, including the expected timing of IND submissions for ONCR-021 and ONCR-GBM; the therapeutic potential and clinical benefits and the utility and potential of the Company’s Synthetic vRNA immunotherapy platform; the Company’s expectations around its GMP facility being fully operational and the benefits of developing in-house manufacturing capabilities and their impact on the Company’s ability to achieve its clinical milestones; and the Company’s belief that its current cash resources will be sufficient to fund its operations and capital expenditure requirements into late 2023. The words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,” “predict,” “future,” “project,” “potential,” “continue,” “target” and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this presentation are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, risks associated with: the impact of COVID-19 or variants thereof on the Company’s operations and the timing and anticipated results of its ongoing and planned preclinical studies and clinical trials; the risk that the preliminary results of preclinical studies or clinical trials may not be predictive of results in future preclinical studies or clinical trials; the Company’s ability to successfully demonstrate the safety, tolerability and efficacy of ONCR-177; the Company’s ability to obtain regulatory approval for ONCR-177 or any of its product candidates; the Company’s ability to advance its preclinical and clinical activities in a timely and cost-effective manner; the Company’s ability to obtain, maintain and protect its intellectual property; the adequacy of the Company’s cash resources and availability of financing on commercially reasonable terms; the accuracy of the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the sufficiency of the Company’s existing capital resources to fund future operating expenses and capital expenditure requirements; and the Company’s anticipated use of existing resources. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on March 10, 2021, as well as discussions of potential risks, uncertainties, and other important factors in the other filings that the Company makes with the Securities and Exchange Commission from time to time. These documents are available under the “SEC filings” page of the Investors section of the Company’s website at http://investors.oncorus.com. Any forward-looking statements in this presentation represent the Company’s views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. They are currently limited by Federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. Disclaimer and Forward-Looking Statements

Slide 3

Heating Up Tumors via Therapeutic Infections Innovative Herpes Simplex Viruses Uniquely engineered to safely retain replication and express 5 immunomodulatory payloads Rapid clinical benefit demonstrated in 3/8 patients thus far with ONCR-177 monotherapy Intratumoral Synthetic RNA Viruses Selectively self-amplifying viral RNA (vRNA) genomes encapsulated in LNPs to avoid neutralizing antibodies and enable repeat IV administration Robust preclinical activity in mice & favorable safety profile in NHPs Intravenous Tumor microenvironments are immunosuppressed & thus susceptible to infections which can rapidly & robustly attract the attention of the immune system Ehrlich & Bacharach, Cancers, (2021); Pol, et al., Cytokine Growth Factor Rev (2020); Melcher, et al., Science 2021

Slide 4

Dual-Platform Informs Robust Pipeline Candidate Platform RoA Indications Discovery IND-Enabling Phase 1 Phase 2 Phase 3 ONCR-177 IL-12, FLT3L, CCL4, aPD-1 & aCTLA-4 HSV iTu Head & Neck Melanoma Triple Neg. Breast ONCR-021 Synthetic CVA21 vRNA IV Non-small cell lung Renal cell Melanoma Hepatocellular ONCR-GBM Multiple payloads HSV iTu Glioblastoma ONCR-788 Synthetic SVV vRNA IV Small cell lung NE prostate Merkel cell Mid ‘22: additional monotherapy data Late ’22: visceral & combination data IND in mid-’23* IND in 2H’23* Oncorus retains worldwide rights to all programs. RoA=route of administration; vRNA=selectively self-amplifying viral RNA; iTu=intratumoral injection; NE=neuroendocrine *contingent upon availability of future funding Monotherapy and combination with

Slide 5

Part A: Monotherapy Part B: Combination with ONCR-177 Phase 1 (KEYNOTE-B73) Clinical Development Plan Randomized Trial(s) 3L TNBC 2L Melanoma 2L Head & Neck ONCR-177 is dosed iTu every 2 weeks for up to 26 doses (NCT04348916); RP2D=Recommended Phase 2 Dose=4E8 for surface lesions; TNBC=triple negative breast cancer *Basket study including breast, squamous cell carcinoma of the head and neck (SCCHN) & melanoma; monotherapy studies also ongoing in patients with visceral disease Treatment Escalations Registration Trials Head & Neck Breast Melanoma RP2D Dose Escalation* Expansions Phase 1 Phase 2/3 Near-Term Objectives: Establish safety and RP2D Demonstrate monotherapy activity Initiate combination studies with pembrolizumab Identify tumor types for registration-directed trials in combination with pembrolizumab

Slide 6

ONCR-177 Phase 1 Monotherapy Provide Early Signs of Clinical Benefit Cut off date:  01Nov2021 Duration of Treatment (Months) CR PR SD PD Death Ongoing Not Evaluable Dose Escalation Cohort 4 (4x108 PFU in 4mL) RP2D​ Dose Expansion Cohorts (4x108 PFU in 4mL) RP2D

Slide 7

Patient 2L Melanoma (4-8) 3L HPV+ SCCHN (4-7) 2L Melanoma (4-6) Prior therapy Relapse after adjuvant nivolumab 2 prior lines including pembrolizumab + platinum ipilimumab + nivolumab, nivolumab Week 4 classification Tumor regression in both lesions, partial response in larger lesion (measurable per RECIST) Investigator reported clinical response in injected lesion Decrease in multiple symptoms before vaginal lesion injection including: vaginal bleeding, discharge, vaginal & pelvic cramping & pain on exam Current status at data cutoff Partial response, as measured by RECIST Continuing on study Progressive disease (non-target lesions), as measured by RECIST & continuing on study Stable disease in nodes; vaginal lesion not measurable by RECIST Continuing on study ONCR-177 Phase 1 Monotherapy Results Provide Early Signs of Clinical Benefit C1D1 (Week 0) C4D1 (Week 6) Rapid clinical benefit observed in 3 patients @ RP2D despite early cut of the data Data cut off 08Nov2021

Slide 8

ONCR-177 Phase 1 Monotherapy Safety & Biomarker Data Treatment-Related Adverse Events at RP2D 4x108 (RP2D)  N=9 4x108 (RP2D)  N=9 Preferred Term Grades 1-2 N (%) Preferred Term  Grades 1-2 N (%) Any Event 7 (77.8) Cellulitis of face 1 (11.1) Fatigue 4 (44.4) Pain in knee 1 (11.1) Injection site pain 1 (11.1) Eyelid twitching 1 (11.1) Rash vesicular 1 (11.1) Dry skin face 1 (11.1) Diarrhea 1 (11.1) Cytokine Release Syndrome 2 (22.2) Vomiting 1 (11.1) Chills 4 (44.4) Decreased appetite 1 (11.1) Nausea 3 (33.3) Headache 1 (11.1) Hypotension 2 (22.2) Hyponatremia 1 (11.1) No Grade ≥3 TRAEs despite replication competent virus Validates proprietary safety strategies Biomarker data from dose escalation suggestive of tumors becoming more responsive to anti-PD-1 T Cell Proliferation (C1D8) Plasma IFNg (C1D2)

Slide 9

Potential ONCR-177 Combination Registration Plans Setting US Market Size Regimen Current Benchmark 2/3L Melanoma  Post anti-PD-1 & anti-CTLA-4 ~6,000 pts/year ONCR-177 + Keytruda vs. investigator’s choice Dacarbazine:  10.3% ORR 2.5 months mPFS 9.1 months mOS1 3L TNBC  2 prior lines of therapy in metastatic setting ~3,200 pts/year ONCR-177 + Keytruda vs. single agent chemo Single agent chemotherapy:  5% ORR 1.7 months mPFS 6.7 months mOS2 2/3L SCCHN  Post anti-PD-1 & post platinum ~18,000 pts/year ONCR-177 + Keytruda vs. investigator’s choice Docetaxel/Cetuximab/Methotrexate Monotx: 10.1 % ORR 2.3 months mPFS 6.9 months mOS3 Phase 1 combination expansion data will inform indications for registration Randomized Phase 2/3 trials to demonstrate benefit in high unmet need settings 1) N Engl J Med 2011; 364:2517-2526. 2) N Engl J Med 2021; 384:1529-1541. 3) Lancet. 2019;393:156-167. 

Slide 10

4x108 selected as RP2D based on safety profile observed to date and preliminary clinical activity Favorable safety profile (no Grade 3+ TRAEs) allows for optionality with combination partners and the opportunity to move into earlier settings, such as neoadjuvant Preliminary biomarker data support systemic inflammatory response as a mechanism of action Combo with systemic anti-PD-1 could reverse immunosuppressive TMEs & enhance activity in non-injected lesions Preliminary but rapid clinical benefit observed in 3/8 patients (melanoma & SCCHN), with prolonged disease stabilization in 6th line TNBC patient 1/4 PRs in melanoma after only 2 injections compares favorably vs. Replimune’s RP2 1/5 PRs in melanoma No monotherapy data presented to date for RP1, which is being developed in melanoma Randomized trials planned for 2/3L melanoma, 3L TNBC, and 2/3L SCCHN Registration efforts to focus on one or more of these indications based on clinical responses and the competitive landscape Upcoming Milestones: Mid 2022 - additional data from surface lesion monotherapy expansion cohorts (approx. 12 pts) Late 2022 - data from surface lesion combination cohorts ONCR-177 Takeaways

Slide 11

Repeat IV administration via selectively self-amplifying viral RNA (vRNA) encapsulated in an LNP vRNA selectively self-amplifies in immunosuppressed environments (tumors) & then produces oncolytic virions which further self-amplify Neutralizing antibodies (nAbs) inhibit efficacy of natural virus but no effect on activity of synthetic RNA virus Anti-tumor activity of native virus abrogated by nAbs Synthetic virus still active in presence of nAbs RNA Virus Synthetic RNA Virus Native virus Native virus + nAb Synthetic virus + nAb Synthetic virus

Slide 12

IV-administered Selectively Self-Amplifying vRNA 1. Ehrlich & Bacharach, Cancers, (2021); 2. Pol, et al., Cytokine Growth Factor Rev (2020) Animated walkthrough of the mechanism here

Slide 13

ONCR-021 is a Selectively Self-Replicating CVA21 Virus IND Filing Expected Mid-’23 ICAM1 expression is prevalent in ONCR-021 selected clinical indications NSCLC HCC RCC 200 um 200 um 200 um Contains the genome of an optimized Coxsackievirus A21 (CVA21) strain, encapsulated in an LNP Oncolytic activity improved over Merck’s CAVATAK strain (Kuykendall) Targets ICAM expressing tumors Indications Patient Samples Tested (N) ICAM+ Prevalence NSCLC 97 72% HCC 69 72% RCC 67 79% Note: CVA21 has established clinical activity in melanoma* *Andtbacka, et al., J Clin Onco., 2021

Slide 14

Well tolerated in huICAM-1 transgenic mouse model ONCR-021: well tolerated w/ min. replication in normal tissues hICAM-1 transgenic mouse model. (-) negative strand RNA indicates active replication. Minimal replication in normal tissues No effects on body weight No adverse elevation of liver enzymes No adverse pathology after single or repeat administration

Slide 15

Preclinical Program ONCR-GBM IND Filing Expected 2H’23 1. Todo, et al, SNO, 2019; 2. Wick, et al, NEJM 2017  3. Wen, et al, N Oncol 2020; 4. Strathdee, et al. IOVC. 2021. GL261-luc-N Model (HSV backbone) (HSV backbone expressing mIL-12) (HSV backbone expressing aPD-1) (HSV backbone expressing mIL-12 & aPD-1) 1st generation: HSV virus has demonstrated unprecedented clinical efficacy1 Teserpaturev (Daiichi-Sankyo) approved in Japan mOS 26.8 months vs. 8-10 months in relapsed GBM2,3 Next generation: leverages Oncorus’ HSV Platform CNS-tailored microRNAs allows for retention of natural IFN resistance Armed with multiple payloads4 Targeting IND in 2H’23

Slide 16

Preclinical Program ONCR-788 for neuroendocrine tumors Encodes selectively self amplifying vRNA encoding for the synthetic Seneca Valley Virus (SVV) Targets SCLC & neuroendocrine prostate Induces tumor regression & improves survival in challenging SCLC xenograft models* Anti-PD-1 combination improves results in murine neuroblastoma model* Leverages learnings from synthetic platform & ONCR-021 Uses similar LNP encapsulation Next generation, proprietary LNP Candidate nominated May ‘21 ONCR-788 (vRNA encoding for SVV) *Kennedy, et al., manuscript under review SCLC Xenograft Model

Slide 17

Technology Virus Virus CpG mRNA mRNA Personalized Cancer Vaccine Programs ONCR-177 RP1, RP2, RP3 CMP-001 mRNA-2752 CV8102 mRNA-4157 BNT122 Immunogenic oncolysis?    -   -  -  -  - Payloads 5 1-3  1 3 1  -  - Antigens Viral + in situ vaccination Viral + in situ vaccination In situ vaccination In situ vaccination In situ vaccination Neoantigens Neoantigens Safety (TRAEs) No Grade 3+ 11% Grade 3+ for RP2 22.5% Grade 3+ No Grade 3+ 12% Grade 3+ No Grade 3+ 9 5% Grade 3+ Single agent ORR in Melanoma 25% (n=4) @ RP2D1 RP1: no single agent data reported RP2: 20% (n=5)2 17.5% (n=40)5 0% (n=5)6 14.3% (n=14)8 No single agent data reported No single agent data reported Combo ORR in Melanoma Study underway RP1: 31% w/ nivo3 RP2: 35.3%* w/ nivo4 23.5% (n=98) w/ pembrolizumab 0% (n=1) w/ durvalumab7 0% (n=3) w/ pembrolizumab10 0% (n=1) w/ atezolizumab11 ONCR-177 has Distinct Advantages Over Other RNA or Viral Immunotherapies *Combined cutaneous & uveal melanoma responses. 1. Park JC, et al. Abstract #511, SITC 2021. 2. Aroldi, et al. Abstract #421 SITC, 2020. 3. REPL corp presentation Nov ’21. 4. Middleton, et al., Abstract #507 , SITC 2021; 5. Mohammed Milhem et al. J Immunother Cancer 2020;8:A186-A187; 6. Patel, et al. Abstract #3092, ASCO, 2020; 7. Patel, et al. Abstract #539, SITC, 2021; 8. Eigentler T, et al. Abstract #1010P, ESMO , 2021; 9. Burris, et al. Abstract #2523, ASCO 2019; 10. Bauman, et al. Abstract #798, SITC 2020; 11. Lopez J, et al, Abstract #CT169, AACR, 2020. ONCR-177 has demonstrated monotherapy activity and with a favorable safety profile that allows for maximum combination partners

Slide 18

IV RNA & Viral Immunotherapy Landscape Viral RNA (vRNA) genome Viral capsid proteins Antibody response Lipid nanoparticle (LNP) Selectively self amplifies and spreads in tumor cells Potential to evade neutralizing antibodies RNA Virus Synthetic RNA virus PEG Lipid Pandha, H., et al., Abstract CT115, slide #18, AACR, 2017.

Slide 19

Multiple Competing Companies Often Win When Transformative New Technologies are Developed Rare for there to be a sole winner when meaningful new technologies are developed, even for the 1st movers Oncorus has distinct technical advantages over others in the viral immunotherapy space Market Cap / Acquisition Price ($M) 2020 PD-(L)1 Sales Merck is the market leader despite BMS’ first-mover advantage & unique access to an approved anti-CTLA-4 (ipilimumab) CRISPR/Cas9 (e.g., Intellia, Beam & CRISPR Tx) is another example RNAi mRNA Viral Immunotherapy *Market cap data pulled from Yahoo Finance on 12/22/21

Slide 20

Robust supply chain is critical to the successful development of any drug candidate & is a strategic asset Better able to respond to unexpected volatility & pressure on supply chains – robustness  Able to manage multiple programs simultaneously – critical to authentic platform companies  Limit burdens of tech transfer and lead time – internal agility In-house manufacturing allows for  Higher quality control & greater operational flexibility Improved control over supply chain  Process development improvements can be more rapidly incorporated into GMP processes Create and Protect 'know-how' in new emerging techniques & process   Delivering Multiple Programs via In-House Manufacturing 105,000 square feet overall, 41,000 square feet in GMP Unit Conference/Huddle Rooms Quality Control Process/Analytical Development Warehouse Office Area GMP Manufacturing

Slide 21

Proven Leadership Team Ted Ashburn, Christophe Quéva, John McCabe, Stephanie  John Goldberg, Steve Harbin Brett Belongia, Lorena Lerner, MD, PhD PhD MBA Duncanson, PhD MD PhD PhD President & CEO CSO CFO VP Strategy & BD SVP Clinical Dev. COO & Chief of Staff VP CMC Operations VP Molecular Biology Board of Directors Ted Ashburn, MD, PhD President & CEO xModerna Mitchell (Mitch) Finer, PhD Chairman & Co-Founder Executive Partner, MPM Capital Mary Kay Fenton, MBA CFO, Talaris Therapeutics xCOO/CFO, Semma/Vertex Eric Rubin, MD SVP Clinical Oncology, Merck & Co Luke Evnin, PhD Co-Founder & Managing Director, MPM Capital Spencer Nam, MBA Managing Partner, KSV Global Scott Canute, MBA xDirector, Immunomedics xGenzyme, xLilly Barbara Yanni, JD xChief Licensing Officer, Merck & Co

Slide 22

Mid-2022 Additional data from surface lesion monotherapy expansion cohorts Late-2022 Data from surface lesion combination cohorts Mid-2023 IND filing for ONCR-021 In-house GMP facility operational Begin registration-directed trials for ONCR-177 2H 2023 IND filing for ONCR-GBM Cash through late 2023* Upcoming Catalysts *Certain activities in 2023 noted above are contingent upon additional financing

Slide 23

Mission is to eradicate cancer by exploiting and enhancing viruses’ natural ability to infect immunosuppressed tumor environments and attract the immune system Preliminary Phase 1 data of iTu ONCR-177 monotherapy demonstrated favorable tolerability, biomarkers to support MOA & rapid clinical benefit in multiple patients Our innovative selectively self-amplifying vRNA platform allows for repeat, systemic administration of a viral immunotherapies to eradicate tumors throughout the body Preclinical data demonstrated ability to evade neutralizing antibodies ONCR-021 shows tumor selective replication, favorable tolerability profile & superior preclinical efficacy compared to native coxsackievirus in NSCLC models 2022 Catalysts: Additional monotherapy data on ONCR-177 surface expansion cohorts in mid-2022 Preliminary data on combination (ONCR-177 + Keytruda) cohorts in late-2022 Advancing Viral Immunotherapies for Cancer

Slide 24

Corporate Presentation January 2022 Viral Immunotherapies for Cancer NASDAQ: ONCR